BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27911676)

  • 1. Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis.
    Patel B; Butterfield JH; Weiler CR; Kane SV
    Monoclon Antib Immunodiagn Immunother; 2016 Dec; 35(6):300-303. PubMed ID: 27911676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
    Kuruvilla M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
    [No Abstract]   [Full Text] [Related]  

  • 3. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.
    Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW
    Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666
    [No Abstract]   [Full Text] [Related]  

  • 4. Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison.
    Motaghi E; Ghasemi-Pirbaluti M; Zabihi M
    Pharmacol Res; 2019 Jan; 139():120-125. PubMed ID: 30395950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab for the treatment of ulcerative colitis.
    Stallmach A; Schmidt C; Teich N
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of vedolizumab and immunomodulators in ulcerative colitis.
    Pinton P
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3556. PubMed ID: 34519096
    [No Abstract]   [Full Text] [Related]  

  • 7. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
    Hedin C; Halfvarson J
    Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis.
    Fratila OC; Craciun C
    J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus Erythematosus.
    Ben-Horin S; Ungar B; Eliakim R; Langevitz P
    J Crohns Colitis; 2016 Jun; 10(6):752-3. PubMed ID: 26826571
    [No Abstract]   [Full Text] [Related]  

  • 10. Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis.
    Belvis Jiménez M; Maldonado Pérez B; Argüelles-Arias F
    J Crohns Colitis; 2018 Aug; 12(9):1134-1135. PubMed ID: 29788419
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypereosinophilic syndrome presenting acutely with neurologic signs.
    Brunet BA; Sugg RM; Stewart P
    Ann Allergy Asthma Immunol; 2018 May; 120(5):461-464. PubMed ID: 29501486
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing biological therapy in Crohn's disease.
    Gecse KB; Végh Z; Lakatos PL
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
    Zoet ID; de Boer NK; de Meij TG
    J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
    [No Abstract]   [Full Text] [Related]  

  • 15. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Mepolizumab on the Lungs in a Boy with Hypereosinophilic Syndrome.
    Armoni Domany K; Shiran SI; Adir D; Lavie M; Levin D; Diamant N; Gut G; Benor S
    Am J Respir Crit Care Med; 2020 Jul; 202(2):e34-e35. PubMed ID: 32150442
    [No Abstract]   [Full Text] [Related]  

  • 17. Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
    Abbenante D; Merli Y; Misciali C; Sacchelli L; Bardazzi F
    Australas J Dermatol; 2022 Feb; 63(1):131-132. PubMed ID: 34817061
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensification of maintenance therapy with infliximab in ulcerative colitis.
    Casellas F
    Rev Esp Enferm Dig; 2015 Sep; 107(9):525-6. PubMed ID: 26334457
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab for ulcerative colitis following liver transplantation.
    Lal S; Steinhart AH
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):277-80. PubMed ID: 17301656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.